ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Ron G.H. Speekenbrink
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Speekenbrink, R. G.H.
Right arrow Articles by Eijsman, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Speekenbrink, R. G.H.
Right arrow Articles by Eijsman, L.

Ann Thorac Surg 1998;66:1998-2002
© 1998 The Society of Thoracic Surgeons

Original Articles

Activation of the protein C system during cardiopulmonary bypass with and without aprotinin

Ron G.H. Speekenbrink, MDa, Rogier M. Bertina, PhDa, Francisco España, PhDa, Charles R.H. Wildevuur, MD, PhDa, Leon Eijsman, MD, PhDa

a Department of Thoracic Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands

Accepted for publication June 4, 1998.

Address reprint requests to Dr Speekenbrink, Department of Thoracic Surgery, Onze Lieve Vrouwe Gasthuis, P.O. Box 95500, 1090 HM Amsterdam, the Netherlands

Background. The protein C system is important in the regulation of hemostasis. We studied its behavior during coronary artery bypass grafting procedures with and without aprotinin treatment using assays sensitive for activation of the protein C system.

Methods. In a prospective, double-blind, randomized study of 48 patients we investigated the levels of antigen to proteins C and S and of the complexes between activated protein C with its two major plasma inhibitors, protein C inhibitor and {alpha}1-antitrypsin in patients treated with placebo (n = 17), low-dose (n = 15), and high-dose (n = 16) aprotinin during elective coronary artery bypass grafting.

Results. The levels of proteins C and S showed a rapid decrease after heparinization, decreased greatly after start of cardiopulmonary bypass, and remained stable during cardiopulmonary bypass. Activated protein C inhibitor complexes were markedly elevated at the start of the procedure. Activated protein C–{alpha}1-antitrypsin decreased greatly after the start of cardiopulmonary bypass and remained stable during cardiopulmonary bypass. A significant peak was observed at the intensive care unit. Activated protein C–protein C inhibitor levels showed a peak after heparinization in accordance with the accelerating effect of heparin on the complex formation but decreased thereafter. Treatment with aprotinin did not notably alter any of the measured patterns.

Conclusions. In this study no evidence was found for increased activation of the protein C system during coronary artery bypass grafting. Administration of aprotinin did not result in different patterns of activation of the protein C system.




This article has been cited by other articles:


Home page
 CirculationHome page
J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor
Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery
Circulation, June 5, 2007; 115(22): 2801 - 2813.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
S. W Sutton, M. A Duncan, V. A Chase, R. J Marcel, T. P Meyers, and R. E Wood
Cardiopulmonary bypass and mitral valve replacement during pregnancy
Perfusion, December 1, 2005; 20(6): 359 - 368.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1998 by The Society of Thoracic Surgeons.